Conduit Pharmaceuticals Inc. has announced a strategic partnership with Manoira to advance the development of AZD1656 and AZD5658 in the animal health sector. This collaboration aims to leverage cutting-edge reformulation expertise to accelerate human clinical programs while exploring commercial potential in the $15 billion animal health market. By entering this joint development agreement, Conduit seeks to generate cross-species insights and fast-track its therapeutic pipeline, all while maintaining full ownership of intellectual property and data. This partnership not only enhances Conduit's core human therapeutic offerings but also opens new revenue opportunities in the growing veterinary market, aligning with its strategy of innovative, high-return collaborations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。